Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 10;15(4):1141.
doi: 10.3390/cancers15041141.

Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study

Eric Leblanc  1   2 , Fabrice Narducci  1   2 , Gwenaël Ferron  3 , Audrey Mailliez  4 , Jean-Yves Charvolin  5 , El Hajj Houssein  1 , Frédéric Guyon  6 , Virginie Fourchotte  7 , Eric Lambaudie  8 , Agathe Crouzet  9 , Yves Fouche  10 , Sébastien Gouy  11 , Pierre Collinet  12 , Frédéric Caquant  13 , Christophe Pomel  14 , François Golfier  15 , Véronique Vaini-Cowen  16 , Isabelle Fournier  2 , Michel Salzet  2 , Emmanuelle Tresch  17 , Alicia Probst  18 , Anne-Sophie Lemaire  19 , Marie-Cécile Le Deley  18   20 , Delphine Hudry  1   2
Affiliations

Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study

Eric Leblanc et al. Cancers (Basel). .

Abstract

Risk-reducing salpingo-oophorectomy is the gold standard for the prophylaxis of ovarian cancer in high-risk women. Due to significant adverse effects, 20-30% of women delay or refuse early oophorectomy. This prospective pilot study (NCT01608074) aimed to assess the efficacy of radical fimbriectomy followed by a delayed oophorectomy in preventing ovarian and pelvic invasive cancer (the primary endpoint) and to evaluate the safety of both procedures. The key eligibility criteria were pre-menopausal women ≥35 years with a high risk of ovarian cancer who refused a risk-reducing salpingo-oophorectomy. All the surgical specimens were subjected to the SEE-FIM protocol. From January 2012 to October 2014, 121 patients underwent RF, with 51 in an ambulatory setting. Occult neoplasia was found in two cases, with one tubal high-grade serous ovarian carcinoma. Two patients experienced grade 1 intraoperative complications. No early or delayed grade ≥3 post-operative complications occurred. After 7.3 years of median follow-up, no cases of pelvic invasive cancer have been noted. Three of the fifty-two patients developed de novo breast cancer. One BRCA1-mutated woman delivered twins safely. Twenty-five patients underwent menopause, including fifteen who had received chemotherapy for breast cancer, and twenty-three underwent menopause before the delayed oophorectomy, while two did not undergo a delayed oophorectomy at all. Overall, 46 women underwent a delayed oophorectomy. No abnormalities were found in any delayed oophorectomy specimens. Radical fimbriectomy followed by delayed oophorectomy appears to be a safe and well-tolerated risk-reducing approach, which avoids early menopause for patients with a high risk of breast and ovarian cancer.

Keywords: delayed oophorectomy; early menopause; high risk of breast and ovarian cancer; ovarian cancer prevention; radical fimbriectomy; risk-reducing surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Participant flow.
Figure 2
Figure 2
Cumulative incidence of oophorectomy from radical fimbriectomy (N = 119).
Figure 3
Figure 3
Cumulative incidence of breast cancer from radical fimbriectomy in patients with no personal history of breast cancer (N = 52).
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Torre L.A., Trabert B., DeSantis C.E., Miller K.D., Samimi G., Runowicz C.D., Gaudet M.M., Jemal A., Siegel R.L. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 2018;68:284–296. doi: 10.3322/caac.21456. - DOI - PMC - PubMed
    1. Ramus S.J., Song H., Dicks E., Tyrer J.P., Rosenthal A.N., Intermaggio M.P., Fraser L., Gentry-Maharaj A., Hayward J., Philpott S., et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women with Ovarian Cancer. JNCI J. Natl. Cancer Inst. 2015;107:djv214. doi: 10.1093/jnci/djv214. - DOI - PMC - PubMed
    1. Mavaddat N., Barrowdale D., Andrulis I.L., Domchek S.M., Eccles D., Nevanlinna H., Ramus S.J., Spurdle A., Robson M., Sherman M., et al. Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) Cancer Epidemiol. Biomark. Prev. 2012;21:134–147. doi: 10.1158/1055-9965.EPI-11-0775. - DOI - PMC - PubMed
    1. Ramus S.J., Antoniou A.C., Kuchenbaecker K.B., Soucy P., Beesley J., Chen X., McGuffog L., Sinilnikova O.M., Healey S., Barrowdale D., et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum. Mutat. 2012;33:690–702. doi: 10.1002/humu.22025. - DOI - PMC - PubMed

LinkOut - more resources